Isma Javed, MD
Internal Medicine · Shawnee, OKNPI 1285087536
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (46.7%), food and beverage and grants — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Abiomed at 25.7% of the total. Reporting peaked in 2022 at $6,288 and has fallen 87.3% since, to $799 in 2025. Among internal medicine clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $98.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$4K
- Abbott$3K
- Boston Scientific$2K
- Philips North America LLC$1K
- Edwards Lifesciences$1K
- Inari Medical, Inc.$1K
- plus $3K from 25 others
What the payments were for
- Grants$1,1057%
- Travel & lodging$7,20247%
- Food & beverage$6,58443%
- Education$5293%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 22 | $3,965 |
| Abbott | 23 | $2,843 |
| Boston Scientific | 25 | $1,620 |
| Philips North America LLC | 8 | $1,306 |
| Edwards Lifesciences | 11 | $1,180 |
| Inari Medical, Inc. | 9 | $1,083 |
| Medtronic(2 entities) | 8 | $852 |
| Merit Medical Systems Inc | 2 | $637 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $261 |
| Cardiovascular Systems Inc. | 2 | $165 |
| Actelion Pharmaceuticals US, Inc. | 5 | $149 |
| Irhythm Technologies, Inc. | 9 | $149 |
| Impulse Dynamics (USA) Inc. | 1 | $139 |
| Penumbra, Inc. | 1 | $138 |
| Teleflex LLC | 2 | $132 |
| Alnylam Pharmaceuticals Inc. | 2 | $123 |
| Asahi Intecc USA, Inc. | 1 | $115 |
| GE HealthCare | 1 | $100 |
| Chiesi USA, Inc. | 1 | $79 |
| Novartis | 2 | $56 |
| Cathworks, Inc. | 1 | $45 |
| Amgen | 2 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Shockwave Medical, Inc | 1 | $35 |
| Kestra Medical Technology Services, Inc. | 1 | $26 |
| Terumo Medical Corporation | 1 | $24 |
| Cardiva Medical, Inc. | 1 | $24 |
| Pfizer | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Bard Peripheral Vascular, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$3,431
- SUPERA$1,400
- GENERAL - STRUCTURAL$1,105
- US Und$1,062
- FLOWTRIEVER CATHETER, S$824
- CT THROMBECTOMY SYSTEM KIT$824
- Edwards SAPIEN 3 Transcatheter Heart Valve$702
- Prelude Ideal Hydrophilic Sheath Introducer$612
- PreludeSync EZ Radial Compression Device$612
- PreludeSync Distal$612
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$316
- ENSITE$294
- OPTIMIZER$278
- Diamondback Coronary$148
- Indigo System$138
- TURNPIKE$127
- HawkOne$122
- MitraClip$120
- LINQ II$119
- ASAHI PTCA Guide Wire$115
How this compares
$15,421 in reported general payments places this provider in the 95th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 133 | $120,196 |
| JardianceEmpagliflozin | 94 | $84,530 |
| BrilintaTicagrelor | 27 | $19,908 |
| XareltoRivaroxaban | 19 | $12,706 |
| Ranolazine ErRanolazine | 125 | $8,706 |
| Repatha SureclickEvolocumab | 14 | $8,101 |
| Amiodarone Hcl | 108 | $3,569 |
| ClopidogrelClopidogrel Bisulfate | 237 | $2,599 |
| Metoprolol Succinate | 206 | $2,268 |
| Atorvastatin Calcium | 219 | $2,035 |
| Amlodipine Besylate | 189 | $945 |
| Nitroglycerin | 77 | $910 |
| Carvedilol | 93 | $754 |
| Rosuvastatin Calcium | 77 | $609 |
| Losartan Potassium | 62 | $572 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $20 | $120,196133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Shawnee
- Steve EgwuonwuLawton$464K
- Jesse RichardsTulsa$279K
- Ryan MorganOklahoma City$235K
- Madhuri LadTulsa$173K
- Stacy ChronisterTulsa$163K
- Layth Al AttarTulsa$35K
- Ali JafryOklahoma City$33K
- Gerard McNultyTulsa$27K
- Yasir UsmanEnid$27K
- Peter LantzTulsa$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.